All Funds

GERM

ETFMG Treatments Testing and Advancements ETF

About GERM

GERM™ is designed to give exposure to the biotech companies engaged in the testing and treatments of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies.

  • Healthcare advancements have had the most impact in combating different diseases, with vaccines, therapies and testing being at the forefront of those developments.
  • Global biotechnology services market is expected to grow from $129.14 billion in 2021 to $151.10 billion in 2022 at a CAGR of 17.0%.6
  • There are over 20 combined epidemic and pandemic-prone diseases affecting the world today.7
  • Variations of coronavirus have been medically documented in approximately 9 instances since 1965.8

About the Fund

The ETFMG Treatments, Testing and Advancements ETF (GERM™) holds U.S.-listed companies engaged in and at the forefront of R&D, vaccines, therapies and testing technologies.

The Fund’s investment objective seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the Prime Treatments, Testing and Advancements Index.

About the Index

The Prime Treatments, Testing and Advancements Index (the “Index”) is an Index of Prime Indexes, a division of Level ETF Ventures LLC. The Index has been created to provide investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.

The Index is designed to include the securities of companies engaged in performing research, development and commercialization of treatments, vaccines or biological testing for infectious diseases. These companies are known collectively as “Treatments, Testing and Advancement Companies.” An investment cannot be made directly in an Index.

Did You Know?

  • The frequency and diversity of disease outbreaks have grown steadily for the past 30 years. Growth in travel, trade and connectivity are key factors.9
  • The global10 vaccines market is one of the fastest-growing biotech segments.11

Prime Indexes

Prime Indexes creates financial indexes that solve problems for both professional and self-directed investors. Prime Indexes are used as the basis for innovative new investment solutions for investors and use intuitive design principles so that new investment products can ultimately provide low-cost, efficient, and convenient access.

For more information, visit www.primeindexes.com.

Research
Fund Summary
Fund Inception
6/17/2020
Ticker
GERM
AUM as of 10/6/2022 1
$22,783,076
CUSIP
26924G763
ISIN
US26924G7631
Stock Exchange
NYSE ARCA
Expense Ratio
0.68%
Intraday NAV (IIV)
GERM.IV
NAV Symbol
GERM.NV
Rebalance Frequency
Quarterly
Index Provider
Prime Indexes
No. of Holdings 2
73
Index Ticker
PGERMN
Income Data
30-Day SEC Yield
as of 10/6/2022 5
0.82%
Security Lending Income 3
0.65
Fund Documents
Related Funds

Fund Prices

Last Updated 10/6/2022

Fund Name

ETFMG Treatments Testing and Advancements ETF

NAV

21.70

Nav Price Change

-0.14

Median Bid/Ask Spread (30 Day) (%) 4

0.42

Symbol

GERM

Market Price Close

21.71

Market Price Changes

-0.09

Premium/Discount (%)

0.06


Month End Performance

Last Updated 09/30/2022

NAV% Market Value%
Cumulative    
1 Month -11.25 -11.35
3 Months -10.87 -10.59
6 Months -23.81 -23.87
YTD -41.65 -41.52
Since Inception Cumulative -15.77 -15.73
Annual    
1 Year -49.14 -49.19
3 Year - -
5 Year - -
Since Inception Annualized -7.23 -7.21

Quarter End Performance

Last Updated 09/30/2022

NAV% Market Value%
Cumulative    
1 Month -11.25 -11.35
3 Months -10.87 -10.59
6 Months -23.81 -23.87
YTD -41.65 -41.52
Since Inception Cumulative -15.77 -15.73
Annual    
1 Year -49.14 -49.19
3 Year - -
5 Year - -
Since Inception Annualized -7.23 -7.21

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance of the Funds may be lower or higher than the performance quoted. All performance is historical and includes reinvestment of dividends and capital gains. Performance data current to the most recent month end may be obtained by calling 1-844-ETF-MGRS (1-844-383-6477).


Top 10 Holdings

Last Updated 10/6/2022

Name % Total Assets Ticker Shares Held Market Value USD
QUEST DIAGNOSTICS INC6.59%DGX11,756$1,501,946.56
ALNYLAM PHARMACEUTICALS INC6.19%ALNY7,018$1,410,758.36
LABORATORY CORP AMER HLDGS6.16%LH6,529$1,403,930.87
BIONTECH SE6.04%BNTX10,031$1,376,152.89
MODERNA INC5.88%MRNA10,670$1,340,365.40
ABCELLERA BIOLOGICS INC4.15%ABCL84,143$944,925.89
BIO RAD LABS INC4.07%BIO2,033$927,068.33
QUIDELORTHO CORP3.91%QDEL12,397$891,592.24
VIR BIOTECHNOLOGY INC3.82%VIR39,141$870,887.25
ZAI LAB LTD3.47%ZLAB21,353$791,555.71

Fund holdings and sector allocations are subject to change at any time and should not be considered recommendations to buy or sell any security.

Premium Discount Chart
Research
Fund Summary
Fund Inception
6/17/2020
Ticker
GERM
AUM as of 10/6/2022 1
$22,783,076
CUSIP
26924G763
ISIN
US26924G7631
Stock Exchange
NYSE ARCA
Expense Ratio
0.68%
Intraday NAV (IIV)
GERM.IV
NAV Symbol
GERM.NV
Rebalance Frequency
Quarterly
Index Provider
Prime Indexes
No. of Holdings 2
73
Index Ticker
PGERMN
Income Data
30-Day SEC Yield
as of 10/6/2022 5
0.82%
Security Lending Income 3
0.65
Fund Documents
Related Funds

Need to know more about this fund?

Contact us

Are you a subject matter expert on this topic?

Let's talk

Get email alerts for all news related to GERM